TARS Tarsus Pharmaceuticals, Inc.

NASDAQ
$79.31

Tarsus Pharmaceuticals, Inc. (TARS) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with TARS's own trailing one-year pace, with 82% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 6 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
6
13 transactions
Purchases
$0
0 shares
Sales
$5.0M
68,367 shares
Net activity
-$5.0M
purchases less sales

How much of that selling was preplanned? 82% planned / 18% discretionary

10b5-1 plan sales $4.1M 12 transactions · 53,971 shares
Discretionary sales $877.4K 1 transaction · 14,396 shares

Largest single sale: $877.4K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Lin Elizabeth Yeu 4 fills Chief Medical Officer Sell 10b5-1 13,953 $87.50 $1.2M 7,933 −63.8% of holding
Azamian Bobak R. 2 fills President/CEO and Board Chair Sell 10b5-1 10,000 $90.56 $905.6K 830,891 −1.2% of holding
Neervannan Seshadri Chief Operating Officer Sell 10b5-1 4,564 $85.00 $387.9K 78,532 −5.5% of holding
Azamian Bobak R. 2 fills President/CEO and Board Chair Sell 10b5-1 10,000 $61.55 $615.5K 853,409 −1.2% of holding
Farrow Jeffrey S See Remarks Sell 14,396 $60.95 $877.4K 56,801 −20.2% of holding
LINK WILLIAM J PHD 2 fills Director Sell 10b5-1 12,500 $62.12 $776.5K 108,714 −10.3% of holding
Goodrich Katherine Director Sell 10b5-1 2,954 $62.08 $183.4K 2,233 −57% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.